Literature DB >> 8940041

Binding affinity of transforming growth factor-beta for its type II receptor is determined by the C-terminal region of the molecule.

S W Qian1, J K Burmester, M L Tsang, J A Weatherbee, A P Hinck, D J Ohlsen, M B Sporn, A B Roberts.   

Abstract

Transforming growth factor-beta (TGF-beta) isoforms have differential binding affinities for the TGF-beta type II receptor (TbetaRII). In most cells, TGF-beta1 and TGF-beta3 bind to TbetaRII with much higher affinity than TGF-beta2. Here, we report an analysis of the effect of TGF-beta structure on its binding to TbetaRII by using TGF-beta mutants with domain deletions, amino acid replacements, and isoform chimeras. Examination of the binding of TGF-beta mutants to the recombinant extracellular domain of TbetaRII by a solid-phase TGF-beta/TbetaRII assay demonstrated that only those TGF-beta mutants containing the C terminus of TGF-beta1 (TGF-beta1-(Delta69-73), TGF-beta1-(Trp71), and TGF-beta2/beta1-(83-112)) bind with high affinity to TbetaRII, similar to native TGF-beta1. Moreover, replacement of only 6 amino acids in the C terminus of TGF-beta1 with the corresponding sequence of TGF-beta2 (TGF-beta1/beta2-(91-96)) completely eliminated the high affinity binding of TGF-beta1. Proliferation of fetal bovine heart endothelial (FBHE) cells was inhibited to a similar degree by all of the TGF-beta mutants. However, recombinant soluble TbetaRII blocked the inhibition of FBHE cell proliferation induced by TGF-beta mutants retaining the C terminus of TGF-beta1, consistent with the high binding affinity between these TGF-beta molecules and TbetaRII. It was further confirmed that the TGF-beta2 mutant with its C terminus replaced by that of TGF-beta1 (TGF-beta2/beta1-(83-112)) competed as effectively as TGF-beta1 with 125I-TGF-beta1 for binding to membrane TbetaRI and TbetaRII on FBHE cells. These observations clearly indicate that the domain in TGF-beta1 responsible for its high affinity binding to TbetaRII, both the soluble and membrane-bound forms, is located at C terminus of the molecule.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940041     DOI: 10.1074/jbc.271.48.30656

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Sequential resonance assignments of the extracellular ligand binding domain of the human TGF-beta type II receptor.

Authors:  A P Hinck; K P Walker; N R Martin; S Deep; C S Hinck; D I Freedberg
Journal:  J Biomol NMR       Date:  2000-12       Impact factor: 2.835

2.  Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site.

Authors:  Y A Muller; B Li; H W Christinger; J A Wells; B C Cunningham; A M de Vos
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

3.  SNAIL Mediates TGF-β1-Induced Downregulation of Pentraxin 3 Expression in Human Granulosa Cells.

Authors:  Hui Li; Hsun-Ming Chang; Zhendan Shi; Peter C K Leung
Journal:  Endocrinology       Date:  2018-04-01       Impact factor: 4.736

Review 4.  Medical applications of transforming growth factor-beta.

Authors:  Kathleen C Flanders; James K Burmester
Journal:  Clin Med Res       Date:  2003-01

5.  Targeting transforming growth factor-β2 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer.

Authors:  Hong Kyu Lee; Hyeong-Jin Ji; Sang-Kyung Shin; Jihye Koo; Tae Hun Kim; Cho-Won Kim; Yeon Hee Seong; Jun-Eui Park; Kyung-Chul Choi
Journal:  Cancer Immunol Immunother       Date:  2022-01-31       Impact factor: 6.630

6.  The role of shear-induced transforming growth factor-β signaling in the endothelium.

Authors:  Tony E Walshe; Nathaniel G dela Paz; Patricia A D'Amore
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-08-22       Impact factor: 8.311

Review 7.  Complexities of TGF-β targeted cancer therapy.

Authors:  Erin C Connolly; Julia Freimuth; Rosemary J Akhurst
Journal:  Int J Biol Sci       Date:  2012-07-12       Impact factor: 6.580

8.  Actin cytoskeleton assembly regulates collagen production via TGF-β type II receptor in human skin fibroblasts.

Authors:  Zhaoping Qin; Gary J Fisher; John J Voorhees; Taihao Quan
Journal:  J Cell Mol Med       Date:  2018-06-11       Impact factor: 5.310

9.  Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1.

Authors:  Xiaobao Fan; Qiannan Zhang; Shuang Li; Yifei Lv; Houqiang Su; Huiping Jiang; Zhiming Hao
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

10.  Binding Properties of the Transforming Growth Factor-β Coreceptor Betaglycan: Proposed Mechanism for Potentiation of Receptor Complex Assembly and Signaling.

Authors:  Maria M Villarreal; Sun Kyung Kim; Lindsey Barron; Ravi Kodali; Jason Baardsnes; Cynthia S Hinck; Troy C Krzysiak; Morkos A Henen; Olga Pakhomova; Valentín Mendoza; Maureen D O'Connor-McCourt; Eileen M Lafer; Fernando López-Casillas; Andrew P Hinck
Journal:  Biochemistry       Date:  2016-12-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.